Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer: a Single Arm, Phase II Clinical Study
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 31 Aug 2018 Biomarkers information updated
- 04 Jan 2018 Planned End Date changed from 30 Nov 2023 to 30 Dec 2023.
- 04 Jan 2018 Planned primary completion date changed from 30 Dec 2022 to 1 Feb 2022.